Abbott Labs Files 8-K on Financial Results & Operations

Ticker: ABT · Form: 8-K · Filed: 2024-01-24T00:00:00.000Z

Sentiment: neutral

Topics: earnings, financial-results, 8-K

TL;DR

**Abbott Labs just dropped an 8-K with their latest financial results, so expect some market reaction.**

AI Summary

Abbott Laboratories filed an 8-K on January 24, 2024, to report its results of operations and financial condition, as well as related financial statements and exhibits. This filing, under Items 2.02 and 9.01, indicates that the company is providing an update on its financial performance. For investors, this matters because it provides crucial, timely information about the company's health and future prospects, which can influence stock price and investment decisions.

Why It Matters

This filing provides investors with the latest financial performance data for Abbott Laboratories, which is essential for evaluating the company's health and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results, which is standard for public companies and does not inherently indicate high risk.

Analyst Insight

Investors should review the full financial statements and exhibits once available to understand the specifics of Abbott Laboratories' performance and adjust their investment thesis accordingly.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Abbott Laboratories?

Abbott Laboratories filed this 8-K to report on its results of operations and financial condition, as well as to furnish related financial statements and exhibits, as indicated under Item 2.02 and Item 9.01.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 24, 2024, which is also the date of the report.

On which stock exchanges are Abbott Laboratories' Common Shares, Without Par Value, registered?

Abbott Laboratories' Common Shares, Without Par Value, are registered on the New York Stock Exchange and the Chicago Stock Exchange, Inc., under the trading symbol ABT.

What is the business address and phone number of Abbott Laboratories as stated in the filing?

The business address for Abbott Laboratories is 100 Abbott Park Road, Abbott Park, Illinois 60064-6400, and their telephone number is (224) 667-6100.

Under which items of Form 8-K did Abbott Laboratories file this report?

Abbott Laboratories filed this report under Item 2.02, 'Results of Operations and Financial Condition,' and Item 9.01, 'Financial Statements and Exhibits.'

From the Filing

0001628280-24-002009.txt : 20240124 0001628280-24-002009.hdr.sgml : 20240124 20240124073644 ACCESSION NUMBER: 0001628280-24-002009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240124 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 24554251 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20240124.htm 8-K abt-20240124 0000001800 FALSE New York Stock Exchange Chicago Stock Exchange, Inc. 0000001800 2024-01-24 2024-01-24 0000001800 exch:XCHI 2024-01-24 2024-01-24 0000001800 exch:XNYS 2024-01-24 2024-01-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 _______________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2024 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) _______________________________________________________ Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification  No.) _______________________________________________________ 100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: ( 224 ) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition On January 24, 2024, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2023. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, a voluntary recall, charges

View on Read The Filing